

## Acute Kidney Injury: global health alert


### Authors

Philip Kam Tao Li<sup>1</sup>  
Emmanuel A. Burdmann<sup>2</sup>  
Ravindra L. Mehta<sup>3</sup>  
For the World Kidney Day  
Steering Committee 2013.

<sup>1</sup> Prince of Wales Hospital,  
Chinese University of Hong  
Kong, Hong Kong, China.

<sup>2</sup> University of São Paulo  
Medical School, São Paulo - SP,  
Brasil.

<sup>3</sup> University of California San  
Diego, San Diego - CA, EUA.



### ABSTRACT

Acute kidney injury (AKI) is increasingly prevalent in developing and developed countries and is associated with severe morbidity and mortality. Most etiologies of AKI can be prevented by interventions at the individual, community, regional and in-hospital levels. Effective measures must include community-wide efforts to increase an awareness of the devastating effects of AKI and provide guidance on preventive strategies, as well as early recognition and management. Efforts should be focused on minimizing causes of AKI, increasing awareness of the importance of serial measurements of serum creatinine in high risk patients, and documenting urine volume in acutely ill people to achieve early diagnosis; there is as yet no definitive role for alternative biomarkers. Protocols need to be developed to systematically manage prerenal conditions and specific infections. More accurate data about the true incidence and clinical impact of AKI will help to raise the importance of the disease in the community, increase awareness of AKI by governments, the public, general and family physicians and other health care professionals to help prevent the disease. Prevention is the key to avoid the heavy burden of mortality and morbidity associated with AKI.

### INTRODUCTION TO WORLD KIDNEY DAY 2013

On March 14, 2013, the 8<sup>th</sup> World Kidney Day (WKD) will be celebrated. WKD is an annual event jointly organized by the International Society of Nephrology and the International Federation of Kidney Foundations. This year, we aim to alert the public to the global increase in acute kidney injury (AKI) in both developing and developed countries. AKI is a syndrome of abrupt loss of kidney function, often with

oliguria, which is strongly associated with increased early and long term patient morbidity and mortality, as well as the subsequent development of chronic kidney disease (CKD). There is an urgent need for a global health strategy to reduce the enormous growing burden of AKI and its consequences. We advocate that efforts focused on preventing AKI be coupled with early detection and treatment, and adequate follow up to reduce mortality and the long term burden of AKI-induced CKD.

#### WKD Steering Committee members:

Miguel Riella (Brazil, co-chair);  
John Feehally (UK, co-chair);  
Timur Erk (Turkey);  
Paul Beerkens (Netherlands);  
Guillermo Garcia-Garcia (Mexico);  
Philip KT Li (Hong Kong);  
William G Couser (USA);  
Georgi Abraham (India);  
Paul Shay (Belgium);  
Luca Segantini (Belgium);  
Sara Martin (Belgium).

DOI: 10.5935/01012800.20130001

## EPIDEMIOLOGY OF AKI WORLDWIDE

The KDIGO (Kidney Disease Improving Global Outcome) Clinical Practice Guideline for AKI, defines AKI as any of the following: increase in serum creatinine by  $\geq 0.3$  mg/dl ( $\geq 26.5$   $\mu\text{mol/l}$ ) within 48 hours; or increase in serum creatinine to  $\geq 1.5$  times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume  $< 0.5$  ml/kg/h for 6 hours.<sup>1</sup> Reports of the incidence of AKI in the community ranged from 2,147 to 4,085 per million population per year (pmp) in developed world.<sup>2,3</sup> Recent hospital studies in the developed world report AKI in 3.2-9.6% of admissions, with overall in-hospital mortality around 20%, and up to 50% in ICU patients.<sup>4,5</sup> AKI requiring renal replacement therapy occurs in 5-6% of ICU patients, with an extremely high in-hospital mortality rate of 60%.<sup>6</sup> It is estimated that about 2 million people die of AKI every year.<sup>6,7</sup> Those who survive AKI have a higher risk for later development of CKD.<sup>8</sup>

### AKI IN THE DEVELOPING WORLD

Eighty-six per cent of the world's population lives in low and middle income countries, where AKI has a peculiar bimodal presentation. In urban areas, the main causes for AKI are renal ischemia, principally due to sepsis, and often associated with nephrotoxic drugs.<sup>9</sup> In rural areas, AKI is usually a community-acquired disease, affecting younger and previously healthy individuals. Specific causes of AKI include diarrheal diseases with dehydration, infectious diseases (malaria, dengue, yellow-fever, leptospirosis, tetanus and human immunodeficiency virus), animal venoms (snakes, bees, spiders, caterpillars), septic abortion, dyes and natural medicines.<sup>10-12</sup> Most of these factors triggering AKI are associated with poverty, poor sanitation and water hygiene (diarrheal diseases), a lack of education and access to an adequate urban infrastructure and healthcare system (septic abortions, snakebite, natural medicines, tetanus) and breaking of an ecological balance from uncontrolled and unplanned urbanization (leptospirosis, yellow-fever, bees and caterpillar accidents).<sup>10-13</sup>

### AKI IN THE DEVELOPED WORLD

The prevalence of AKI in the developed world has increased in the last decade.<sup>14,15</sup> AKI is now encountered in 45% of patients admitted to the ICU and 20% of hospitalized patients.<sup>16,17</sup> This increased prevalence likely reflects an aging population burdened

by multiple co-morbidities, which is often managed with multiple drugs.<sup>18,19</sup> AKI is a multifactorial entity. Etiological factors include prerenal injury contributing to reduced renal perfusion, precipitated by iatrogenic events e.g. hypotension during anesthesia and surgery, or profound diarrhea secondary to *C. difficile* infection resulting from aggressive antibiotic therapy.<sup>20</sup> Drug induced kidney injury, hospital acquired infections, sepsis, complex surgery and diagnostic procedures requiring intravenous contrast are significant risk factors for development of AKI.<sup>21-23</sup> Patients in the ICU are dying of AKI and not just simply with AKI. In the developed world, patients are increasingly cared for by multiple providers, often in different health care systems, with infrequent or minimal data sharing. This lack of knowledge often results in overdosing of nephrotoxic medications, like non-steroidal anti-inflammatory drugs (NSAIDs). A recent national audit of the care provided to patients who died with a diagnosis of AKI in United Kingdom hospitals revealed several shortcomings: AKI was often diagnosed late, the initial severity underestimated, and diagnostic and therapeutic interventions often incomplete or delayed.<sup>24</sup> This audit illustrates the urgent need for improving awareness of AKI and has prompted the medical community in the UK to implement specific measures to facilitate early recognition, timely diagnosis, and appropriate management and follow up of AKI patients.<sup>25</sup>

### AKI IN CHILDREN

The epidemiology of pediatric AKI has shifted in the last decades from intrinsic kidney diseases such as hemolytic uremic syndrome and glomerulonephritis to ischemia, nephrotoxins and sepsis in critically ill children.<sup>17</sup> The incidence of AKI is clearly increasing. Development of AKI is an independent risk factor for death in children, from neonates to adolescents. Recently, the concept of 'renal angina' was proposed and one of the strongest indicators of 'renal angina' and risk of further development of AKI in children is fluid overload.<sup>17,26</sup> As in adults, AKI carries a significant risk for late development of CKD in surviving children.<sup>17,27</sup>

### OTHER CONSEQUENCES OF AKI

Patients with AKI utilize more resources and have longer hospital lengths of stay in part due to effect of AKI on other organ function: more difficulty being

weaned off artificial ventilation, greater risk of fluid overload with a resultant increase in mortality, and impaired renal recovery and more prolonged recuperation. AKI contributes to CKD development and may result in dialysis dependency. Collectively these data demonstrate the high personal and community costs of an episode of AKI and stress the pressing need to address this problem in an effective way.<sup>28</sup>

### IS AKI PREVENTABLE AND TREATABLE?

A central tenet of the WKD message since 2006 has been that “kidney disease is common, harmful and treatable”. Like CKD, AKI is common, harmful and treatable, and is also largely preventable. The heterogeneity of patients and the broad range of situations where AKI is encountered make it challenging to standardize an approach for evaluating and managing patients with this syndrome. The recent KDIGO guidelines for management of AKI provide a useful reference to assist clinicians for managing AKI, however the successful implementation of guidelines and their application to individual patients can be slow and requires concerted efforts.<sup>1,29</sup>

Prevention of AKI starts in the community with prompt assessment of those at risk, for example in taking prompt action following effective evaluation of the severity of fluid depletion in acute diarrhea. Regular drug therapy can compound that risk and the many older people taking NSAIDs or renin-angiotensin system blockers should be educated to discontinue them temporarily in the face of acute intercurrent illness, a so-called “medication holiday”.

In the developed world, the growing adoption of electronic medical records (EMRs) assists continuity of outpatient and in-hospital care. Active surveillance for changes in creatinine can automate alerts to guide drug dosing and reduce the incidence of drug-induced kidney injury.<sup>30,31</sup> An “AKI sniffer system” embedded in the EMR to warn physicians of changing renal function has been shown to increase the number and timeliness of early therapeutic interventions.<sup>32</sup> Currently serum creatinine and urinary volume remain the clinical pointers to AKI diagnosis. Given advances in medical informatics, biomarker development and interpretation, and therapeutic interventions, physicians and care providers should be educated about AKI and also the tools to manage these patients timely and effectively.

In the hospital setting, AKI preventive measures include adequate hemodynamic control, hydration, hematocrit and oxygen profiling, avoidance of nephrotoxic drugs and preventive maneuvers for particular diseases or conditions causing AKI. In the developing world, awareness of the specific infectious or venomous organisms in certain areas will allow environmental protection, vaccines, pharmacologic prophylaxis, and early administration of anti-venom. Prompt diagnosis, early treatment, timely hemodialysis and adequate supportive therapy are associated with improved outcome in AKI.<sup>10,33,34</sup>

Prevention for AKI is clearly the key to avoid the heavy burden of mortality and morbidity associated with this syndrome (Table 1), and this will only come about through increasing awareness of the true incidence and clinical impact of AKI among governments, the public, general and family physicians and other health care professionals. Most etiologies of AKI can be prevented by interventions at the individual, community, regional and in-hospital levels. Effective measures must include community-wide efforts to increase an awareness of the devastating effects of this illness and provide guidance on preventive strategies and for early recognition and management. Efforts should be focused on minimizing AKI causes, increasing awareness of the importance of serial measurements of serum creatinine in high risk patients and observing urinary volume to achieve early diagnosis. Protocols need to be developed to systematically manage prerenal conditions and specific infections.

### RENAL REPLACEMENT THERAPY FOR AKI

When AKI patients require renal replacement therapy (RRT), the current KDIGO recommendations are to deliver an effluent volume of 20-25 ml/kg/h for continuous renal replacement therapy (CRRT) or to deliver a Kt/V of 3.9 per week when using intermittent or extended RRT.<sup>1</sup> Peritoneal dialysis (PD) should also be considered for AKI, particularly in developing countries, because it is a simple, effective, safe and relatively inexpensive form of RRT.<sup>1,35</sup>

### CONCLUSION

The worldwide celebration of World Kidney Day 2013 provides an opportunity to share the message that acute kidney injury is indeed common, harmful, preventable and treatable, and that protecting the

**TABLE 1** STRATEGIES FOR PREVENTING AKI

Action level	Strategies for preventing AKI
Government	Funding support for AKI research in hospital and community on AKI incidence, outcome and mortality.
	Funding support for setting up AKI registries.
	Recognition of natural hazards for AKI: water sanitation, flooding, venomous animals.
	Recognition of AKI in common infections : malaria, dengue, leptospirosis, HIV, postinfectious hemolytic uremic syndrome.
Public	Better obstetric care.
	Collaboration with healthcare professionals on educating the public about AKI prevention.
General practitioners and physicians	Aware of the potential problems of AKI and avoid unsupervised, indiscriminate and long term use of nephrotoxic drugs and natural substances.
	Awareness of patients at risk for AKI and situations contributing to AKI.
	Aware of pre-renal causes of AKI and of the need for early and appropriate rehydration and hemodynamic optimization in hypovolemic patients.
	Aware of natural and man-made nephrotoxin, nephrotoxic drugs, herbs and indigenous medicine.
Nephrologists	Judicious use of nephrotoxic drugs and aware of potential drug interactions.
	Early recognition of AKI and early referral to nephrologists.
	Establish and implement common AKI diagnostic criteria and definitions for prevention, treatment and research.
	Find new diagnostic tools including inexpensive technology and biomarkers for AKI diagnosis and monitoring.
	Adapt renal replacement therapy to regional needs, technique and resource availability.

kidneys from this lethal syndrome is an important health strategy for the patient and the community. The effective implementation of such strategies will only come when both the general public and the renal community work together to convince health authorities of the pressing need to do this. Government and health authorities must allocate resources to manage this problem both in the developed and developing world.

## REFERENCES

1. KDIGO. Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int* 2012; (Suppl) 2: 1-138.
2. Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. *J Am Soc Nephrol*. 2007;18:1292-8.
3. Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. *Kidney Int* 2007;72:208-12.
4. Fang Y, Ding X, Zhong Y, et al. Acute kidney injury in a Chinese hospitalized population. *Blood Purif*. 2010;30:120-6.
5. Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. *J Am Soc Nephrol*. 2010;21:345-52.
6. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA*. 2005;294:813-8.
7. Murugan R, Kellum JA. Acute kidney injury: what's the prognosis? *Nat Rev Nephrol*. 2011;7:209-17.
8. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. *Kidney Int* 2012;81:442-8.
9. Santos WJ, Zanetta DM, Pires AC, et al. Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit - a homogeneous population? *Crit Care* 2006;10:R68.
10. Lombardi R, Yu L, Younes-Ibrahim M, et al. Epidemiology of acute kidney injury in Latin America. *Semin Nephrol*. 2008;28:320-9.
11. Naicker S, Aboud O, Gharbi MB. Epidemiology of acute kidney injury in Africa. *Semin Nephrol*. 2008;28:348-53.
12. Jha V, Rathi M. Natural medicines causing acute kidney injury. *Semin Nephrol*. 2008;28(4):416-28.
13. Abdulkader RC, Barbaro EJ, et al. Nephrotoxicity of insect and spider venoms in Latin America. *Semin Nephrol*. 2008;28:373-82.
14. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11:R31.
15. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN--time for reappraisal. *Crit Care* 2009;13:211.
16. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. *Lancet* 2012;380:756-766.
17. Goldstein SL. Acute kidney injury in children and its potential consequences in adulthood. *Blood Purif* 2012;33:131-7.
18. Chronopoulos A, Cruz DN, Ronco C. Hospital-acquired acute kidney injury in the elderly. *Nat Rev Nephrol*. 2010;6:141-9.
19. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. *Clin J Am Soc Nephrol* 2008;3:844-61.
20. Cerda J, Lameire N, Eggers P, et al. Epidemiology of acute kidney injury. *Clin J Am Soc Nephrol* 2008;3:881-6.
21. Perazella, MA. Drug use and nephrotoxicity in the intensive care unit. *Kidney Int* 2012;81:1172-8.
22. Zarjou A, Agarwal A. Sepsis and acute kidney injury. *J Am Soc Nephrol*. 2011;22:999-1006.

23. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. *Circulation* 2010;122:2451-5.
24. MacLeod A. NCEPOD report on acute kidney injury- must do better. *Lancet* 2009;374:1405-6.
25. Prescott AM, Lewington A, O'Donoghue D. Acute kidney injury: top ten tips. *Clin Med*. 2012;12:328-32.
26. Basu RK, Chawla LS, Wheeler DS, et al. Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. *Pediatr Nephrol*. 2012;27:1067-78.
27. Mammen C, Al Abbas A, Skippen P, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. *Am J Kidney Dis*. 2012;59:523-30.
28. Li PK, Chow KM, Matsuo S, et al. Asian Chronic Kidney Disease (CKD) Best Practice Recommendations - Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). *Nephrology* 2011 (Carlton); 16: 633-41.
29. Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. *Nephrol Dial Transplant* 2012;27:4263-72.
30. Cho A, Lee JE, Yoon JY, et al. Effect of an electronic alert on risk of contrast-induced acute kidney injury in hospitalized patients undergoing computed tomography. *Am J Kidney Dis* 2012;60:74-81.
31. Cox ZL, Nelsen CL, Waitman LR, et al. Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. *Am J Health Syst Pharm* 2011;68:624-32.
32. Colpaert K, Hoste EA, Steurbaut K, et al. Impact of real-time electronic alerting of acute kidney injury on therapeutic intervention and progression of RIFLE class. *Crit Care Med* 2012;40:1164-70.
33. Andrade L, Daher EF, Seguro AC. Leptospirosis nephropathy. *Semin Nephrol*. 2008;28:383-94.
34. Cerdá J, Bagga A, Kher V, Chakravarthi RM. The contrasting characteristics of acute kidney injury in developed and developing countries. *Nat Clin Pract Nephrol*. 2008;4:138-53.
35. Ponce D, Berbel MN, Goes CR, et al. High-volume peritoneal dialysis in acute kidney injury: indications and limitations. *Clin J Am Soc Nephrol*. 2012;7:887-94.